The long-term trend of the EPS is a vital number as it helps understand the future potential of Coca Cola Femsa S.A.B. De C.V.. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 4.00 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Coca Cola Femsa S.A.B. De C.V. is making for it’s investors or shareholders.

Coca Cola Femsa S.A.B. De C.V. is in the non-alcoholic beverages industry and is in the consumer defensive sector. The company CEO is John Anthony Santa Maria Otazua. Coca-Cola Femsa SAB de CV caters to the beverage industry. It is a franchise bottler of Coca-Cola trademark beverages.

Previous Intraday Performance:

The KOF shares had a previous change of 0.59% which opened at 64.02 and closed at 64.58. It moved to an intraday high of 64.59 and a low of 63.48.

SeekingAlpha:  Tracking Tweedy Browne Portfolio – Q3 2018 Update

Historical Performance:

Over the last five trading days, KOF shares returned 4.36% and in the past 30 trading days it returned 5.25%. Over three months, it changed 4.99%. In one year it has changed -7.17% and within that year its 52-week high was 79.42 and its 52-week low was 54.53. KOF stock is 18.43% above its 52 Week Low.

Our calculations result in a 200 day moving average of 60.33 and a 50 day moving average of 60.39. Right now, KOF stock is trading 7.04% above its 200 day moving average.

SeekingAlpha:  Tracking Tweedy Browne Portfolio – Q3 2018 Update


The company has a market cap of $13.6b with 210.1m shares outstanding and a float of 210.1m shares. Trading volume was 57,617 shares and has experienced an average volume of 86,346 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Coca Cola Femsa S.A.B. De C.V. was -3.11 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.91. The trailing twelve month EPS is 3.00, which comes to a trailing twelve month PE of 21.53.

Below was the last reported quarterly earnings per share:
09-30-2018:  0.72
06-30-2018:  0.69
03-31-2018:  0.61
12-31-2017:  0.98

The dividend per share is currently 1.66, which is a dividend yield of 2.57%. Also, the payout ratio is 55.33%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 88.41, which means it might be undervalued and has a margin of safety of 26.95%

Indicators Also to Watch:

Based on the latest filings, there is 8.40% of institutional ownership. Short-interest was 65,309, which was 0.03% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.62. This stock has some short interest, but it might be normal and no need to worry if long the position.

I calculated the beta to be 0.76

SeekingAlpha:  Marrone Bio Innovations, Inc. (MBII) CEO Pamela Marrone on Q3 2018 Results – Earnings Call Transcript

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -12.52%, return on assets is -5.22%, profit margin is 6.83%, price-to-sales is 1.29 and price-to-book is 2.20.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 3  : Financial Safety Result
 1  : Past Performance Result
 2  : Valuation Result
 4  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here